New shot could stop chronic hives when antihistamines fail

NCT ID NCT06228560

Completed Disease control Sponsor: Longbio Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested a new injectable drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't control. The study compared LP-003 to a placebo and to an existing drug (omalizumab) to see if it could completely stop wheals and itching by week 12. The goal is to find a better option for people whose hives don't respond to usual treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-003 (an injectable biologic drug)
What this could lead to: If successful, LP-003 could offer a new treatment option for people with chronic hives that don't respond to standard antihistamines.
What could go wrong: This is an early Phase 2 study with only 202 participants, so results may not hold up in larger trials. The drug may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Affiliated Hospital of Jiangsu University

Zhenjiang, China
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China
Fujian Medical University Union Hospital

Fuzhou, Fujian, China
Hangzhou First People's Hospital

Hangzhou, China
Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College

Nanjing, Jiangsu, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China
Peking University Third Hospital

Beijing, Beijing Municipality, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China
Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, China
The First Affiliated Hospital of China Medical University

Beijing, Beijing Municipality, China
The First Affiliated Hospital of PLA Army Medical University

Chongqing, Chongqing Municipality, China
The First Hospital of Peking University

Beijing, Beijing Municipality, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, China
The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
The Second XiangYa Hospital of Central South University

Changsha, Hunan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
Wuhan NO.1 Hospital

Wuhan, China
the Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.